Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477825 · ClinicalTrials.gov registry record · NA
Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin
A NA study of Erythema and Wrinkles, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03477825 is a NA study of Erythema and Wrinkles that has completed, run by University of California, Davis. The registered enrollment target is 35 participants, below the 105-participant average among 9 other Erythema trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03477825, a NA study of Erythema and Wrinkles, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Few studies have assessed the effects of Triphala and Rubia Cordifolia from a skin biophysical perspective. Here, we aim to understand how these herbs can modulate the skin's barrier properties and the gut microbiome.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo Oral Tablet
- DIETARY_SUPPLEMENT Rubia Cordifolia
- DIETARY_SUPPLEMENT Triphala
Study Locations (1)
California
- University of California-Davis, Department of Dermatology - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2019-01-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03477825
The ClinicalTrials.gov registry entry for NCT03477825 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 9 other Erythema trials with a reported enrollment target (67% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Erythema appearing as the primary indexed condition, and to 3 interventions - of which Placebo Oral Tablet is the first listed.
NCT03477825 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03477825 about?
NCT03477825 is a clinical study titled "Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin". Few studies have assessed the effects of Triphala and Rubia Cordifolia from a skin biophysical perspective. Here, we aim to understand how these herbs can modulate the skin's barrier properties and the gut microbiome.
What is the current status of trial NCT03477825?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2018-03-12. Estimated completion is 2019-01-25.
What conditions does trial NCT03477825 study?
This clinical trial studies the following conditions: Erythema, Wrinkles, Sebum Production, Stool Microbiome, Transepidermal Water Loss.
What interventions are being tested in trial NCT03477825?
The interventions under investigation include: Placebo Oral Tablet (DIETARY_SUPPLEMENT), Rubia Cordifolia (DIETARY_SUPPLEMENT), Triphala (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03477825?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03477825 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erythema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Human Repeat Insult Patch Test to Evaluate Personal Lubricants
COMPLETED · NA
-
A Comparison of INSORB Staples With Metal Staples in Total Hip Replacement
COMPLETED · NA
-
A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects
COMPLETED · NA
-
A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects
COMPLETED · NA
-
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.